Proteomic signature of tubulointerstitial tissue predicts prognosis in IgAN

BMC Nephrol. 2022 Mar 24;23(1):118. doi: 10.1186/s12882-022-02736-4.

Abstract

Background: IgA nephropathy (IgAN) is associated with a significant risk of progression to kidney failure. Tubular atrophy is an established important risk factor for progressive disease, but few studies have investigated tubulointerstitial molecular markers and mechanisms of progression in IgAN.

Methods: Based on data from the Norwegian Renal Registry, two groups were included: IgAN patients with (n = 9) or without (n = 18) progression to kidney failure during 10 years of follow-up. Tubulointerstitial tissue without discernible interstitial expansion or pronounced tubular alterations was microdissected, proteome was analysed using tandem mass spectrometry and relative protein abundances were compared between groups.

Results: Proteome analyses quantified 2562 proteins with at least 2 unique peptides. Of these, 150 proteins had significantly different abundance between progressive and non-progressive IgAN patients, 67 were more abundant and 83 less abundant. Periostin was the protein with the highest fold change between progressive and non-progressive IgAN (fold change 8.75, p < 0.05) and periostin staining was also stronger in patients with progressive vs non-progressive IgAN. Reactome pathway analyses showed that proteins related to inflammation were more abundant and proteins involved in mitochondrial translation were significantly less abundant in progressive vs non-progressive patients.

Conclusions: Microdissection of tubulointerstitial tissue with only mild damage allowed for identification of proteome markers of early progressive IgAN. Periostin abundance showed promise as a novel and important risk marker of progression.

Keywords: ESRD; Formalin-fixed paraffin embedded kidney biopsy tissue; IgA nephropathy; Liquid chromatography–tandem mass spectrometry; Proteomic analyses; Tubulointerstitium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Disease Progression
  • Female
  • Glomerulonephritis, IGA* / complications
  • Glomerulonephritis, IGA* / diagnosis
  • Humans
  • Male
  • Prognosis
  • Proteome
  • Proteomics
  • Renal Insufficiency* / complications

Substances

  • Biomarkers
  • Proteome